Ukubuza ukuba Utywala Ukhuselekile kangakanani
Kuyavuma kakuhle ukuba umntu onesifo esingapheliyo sesifo se- hepatitis C kunye nembali yokusetyenziswa kakubi kotywala ngokweqile kunethuba elongezelelweyo lokuhlakulela isifo sesibindi esiphezulu, kubandakanya i- cirrhosis kunye ne- hepatocellular carcinoma (uhlobo lwesifo somhlaza wesibindi). Ezi zombini le meko zisebenza kunye ukuphucula ngokufanelekileyo uphuhliso, ukuqhubela phambili, kunye nokubandezeleka kwesifo sesibindi .
Ngokwabo, ukungenisa utywala obunzima kunokukhokelela kwindlela yokungabikho kwintsholongwane ye-hepatitis ebizwa ngokuba yi-hepatitis yotywala. Xa ubhanjiswe ne-hepatitis yentsholongwane (ngohlobo lwe- hepatitis B okanye i-hepatitis C), impembelelo yesibindi inokunyuka kakhulu.
I-Hepatitis C sele ifunyenwe ngokuqhelekileyo kubantu abanomdla wokusetyenziswa kakubi kotywala kunokuba bangabinxila. Nangona izizathu ezi zinto zingacacile ngokupheleleyo, siyazi ezimbini izinto:
- Ukusetyenziswa kotywala kunye nokusetyenziswa kweziyobisi kusetyenziswe kakhulu, kwaye;
- Ukusetyenziswa kweziyobisi ezisetyenziswayo kuseyona ndlela ephezulu yokuthunyelwa kwe-hepatitis C e-US
Le mibutho igxininisa imfuno yokujongana nokusela utywala kubo bonke abantu abane-hepatitis C engapheliyo, ingaba impawu okanye ayikho; kunye nokujongana nokusetyenziswa kotywala nanini na ukuqala isicwangciso sokukhusela i-HCV, ingakumbi phakathi kwabasebenzisi abasebenzisa iziyobisi kunye namanye amaqela aphezulu.
Phakathi kweengozi ezinxulumene nokusetyenziswa kotywala kunye ne-hepatitis C:
Umngcipheko ophezulu we-Cirrhosis
Akungabazeki ukuba abantu abanesifo esingapheliyo sesifo se-hepatitis C abasela isiselo esinxilisayo banethuba eliphezulu lokuphucula i- cirrhosis . Ukusuka kwindawo yokujonga i-epidemiological, abangaphezu kwama-90% abantu abaphuza kakhulu (abachazwa ngokucacileyo njengabesifazana abaneziphuzo ezimbini kwiintsuku kunye nabesilisa abaneziyobisi ezintathu ngosuku) baya kuhlakulela isifo sesibindi esinamafutha , apho kukho i-20% i-cirrhosis yesibindi kwiminyaka eyi-10-20.
Ukusuleleka kwe-Hepatitis C kuqhuba inkalo efanayo, kunye nabantu abangama-75% abanesifo abanezifo ezingapheliyo, ngelixa i-15-20% iya kuqhubela phambili kwizifo eziphambili kwiminyaka eyi-10 ukuya kwe-30.
Ukudibanisa kwezi zinto zimbini zihamba nje ngokukhawuleza inkqubo leyo, kunye nokwandisa ubunzima obunobungozi besibindi-ngoqikelelo oluthile, ngo-200-300%. Ngaphezu koko, abasebenzisi abasebenzisa utywala obukhulu kunye neHCV banomngcipheko omkhulu wokuba ne-cirrhosis abangaphezu kwabangasayi basebenzisa iHCV.
Ukwandisa ingozi ye-Hepatocellular Carcinoma
I-Hepatocellular carcinoma (i-HCC) yindlela eqhelekileyo yomhlaza wesibindi e-US kwaye enye yeengxaki eziqhelekileyo zentsholongwane engapheliyo ye-hepatitis C. Ngaphezulu kune-cirrhosis yesibindi, umbutho phakathi kokusela utywala kunye ne-HCC inamandla, kunye nama-80% ama-HCC matyala achongwa njengabasebenzisi abasebenzisa utywala obukhulu.
Umngcipheko ubonakala ukwanda kunye nemali umntu aselayo. Olunye uphando lwe-Italiya lubonise ukuba ubukho beHCC buphindwe kabini xa umntu ephuza phakathi kwezi-3.4 no-6.7 iziphuzo ngosuku. Ngokufanayo, uphando lubonise ukuba ukusela kakhulu kunokukhawulezisa ukuphuhliswa kwe-HCC ngeminyaka emihlanu, okubangelwa ukuba kungekhona nje izicubu ezinkulu kuphela kodwa zihlala zifutshane.
Ukuphuculwa koPhulo lweePrapeferfer-based based therapy
Nangona i- peginterferenon isetyenziswa kakhulu ngaphantsi kweyonyango yeHCV yanamhlanje, iyaqhubeka isetyenziswa kwiimeko apho kukho ukuphulukana kwangaphambili kwonyango kunye / okanye ukuxilongwa kwesifo sesibindi esiphezulu.
Okumangalisa kukuba, ngokuqhelekileyo izigulane ezineembali zokusetyenziswa kakubi kotywala ezifuna i-peginterferon-based based
Utywala luphazamisa ukuphumelela kwe-peginterferon, okubangela ukuba ingozi ye-300% yokuguquka kwentsholongwane (oko kukuthi, ukubuya kwintsholongwane) emva kokugqitywa kweyeza. Okumangalisa kukuba, umngcipheko wokungaphumeleli wawubonakala ufana phakathi kokubini kunye nabaphuza kakhulu xa befaniswa nabangewona abaphuza ngeHCV.
Ubuninzi Kangakanani Utywala?
Okwangoku akucaci ukuba ixesha elide isigulane kufuneka libale utywala ngaphambi kokuba imiphumo emibi yokusetyenziswa kakubi kotywala iguqulwe. Kungenxa yesi sizathu sokuba ukupheliswa kotywala (kunye neprogram yonyango, xa kuyimfuneko) kuhloliswe njengenxalenye yesicwangciso sonyango kubantu abane-HCV yokusuleleka kwintsholongwane engapheliyo, ngakumbi abo bafumene i -cirrhosis ehlawulelwe okanye ehlawulwe .
Ukongezelela, izigulane ezifuna i-peginterferon zicetyiswa ukuba ziyeke ubuncinane kwiinyanga ezintandathu ngaphambi kokuqala unyango kwaye kufuneka zicetyiswe ukuba ziyeke ukusetyenziswa kotywala ngaphezu kweenyanga ezintandathu emva kokugqitywa kweyeza.
Imithombo:
Mueller, S .; Millonig, G; kunye noSeitz, H. "Isifo sesibindi sokunxila, kunye nesifo se-hepatitis C: Ukudibanisa rhoqo." I-World Journal yeGastroenterology. Julayi 28, 2009; 15 (28): 3462-3471.
Iziko zeSizwe zezeMpilo (NIH). "I-Hepatitis C kunye noTywala." EBethesda, eMaryn; papashwe ngoSeptemba 29, 2004.